MX2020004683A - Metodos de inmunoterapia oral. - Google Patents
Metodos de inmunoterapia oral.Info
- Publication number
- MX2020004683A MX2020004683A MX2020004683A MX2020004683A MX2020004683A MX 2020004683 A MX2020004683 A MX 2020004683A MX 2020004683 A MX2020004683 A MX 2020004683A MX 2020004683 A MX2020004683 A MX 2020004683A MX 2020004683 A MX2020004683 A MX 2020004683A
- Authority
- MX
- Mexico
- Prior art keywords
- peanut
- peanut allergy
- subject
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripción se refiere a métodos mejorados de inmunoterapia oral para tratar alergias alimentarias. y particularmente alergia al cacahuate. Los biomarcadores. tales como un nivel de IgEs específicas de cacahuate y/o IgG4 especifica de cacahuate se usan mediante los métodos descritos en este documento. Dichos métodos incluyen un método para tratar a un sujeto para una alergia al cacahuate. métodos para evaluar la idoneidad de un tratamiento para una alergia al cacahuate. un método para evaluar un síntoma en un sujeto durante el curso del tratamiento de una alergia al cacahuate, un método para monitorizar el tratamiento para una alergia al cacahuate en un sujeto. un método para reducir el riesgo o la incidencia de un evento adverso en un sujeto que recibe tratamiento para una alergia al cacahuate, un método para ajustar una dosis de una composición alérgena de cacahuate y un método para evaluar una probabilidad de una reacción alérgica que requiera la administración de epinefrina a un sujeto que recibe tratamiento para una alergia al cacahuate.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762580999P | 2017-11-02 | 2017-11-02 | |
| US201862631406P | 2018-02-15 | 2018-02-15 | |
| US201862637903P | 2018-03-02 | 2018-03-02 | |
| US201862674478P | 2018-05-21 | 2018-05-21 | |
| PCT/US2018/058777 WO2019089978A1 (en) | 2017-11-02 | 2018-11-01 | Methods of oral immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004683A true MX2020004683A (es) | 2020-08-13 |
Family
ID=66332382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004683A MX2020004683A (es) | 2017-11-02 | 2018-11-01 | Metodos de inmunoterapia oral. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11369676B2 (es) |
| EP (1) | EP3703743A4 (es) |
| KR (1) | KR20200083526A (es) |
| CN (1) | CN111344010A (es) |
| AU (1) | AU2018358125A1 (es) |
| CA (1) | CA3080601A1 (es) |
| MX (1) | MX2020004683A (es) |
| WO (1) | WO2019089978A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105101994B (zh) | 2013-03-14 | 2018-10-12 | 艾慕恩治疗公司 | 用于口服脱敏的花生制剂的制备 |
| EP3185900A4 (en) | 2014-08-25 | 2018-05-02 | Aimmune Therapeutics, Inc. | Egg protein formulations and methods of manufacture thereof |
| CN111629721A (zh) | 2017-12-06 | 2020-09-04 | 百乐吉公司 | 用于减少过敏反应的组合物和方法 |
| EP3829632A4 (en) | 2018-07-27 | 2022-05-04 | Société des Produits Nestlé S.A. | SYSTEMS AND METHODS FOR DELIVERING UNIT DOSES OF ORAL IMMUNOTHERAPY |
| WO2020100024A1 (en) * | 2018-11-12 | 2020-05-22 | Murdoch Childrens Research Institute | Method and system |
| CN113891722A (zh) * | 2018-12-20 | 2022-01-04 | 爱沐疗法公司 | 用于漏服剂量的花生口服免疫疗法给药计划表 |
| AU2020276213A1 (en) | 2019-05-10 | 2021-10-28 | Société des Produits Nestlé S.A. | Methods for improving the quality of life of a patient with a peanut allergy |
| JP2023506028A (ja) * | 2019-12-23 | 2023-02-14 | プロタ セラピューティクス ピーティワイ リミテッド | 医薬組成物 |
| WO2022089595A1 (en) * | 2020-10-30 | 2022-05-05 | Oneness Biotech Co., Ltd. | Biomarkers for ige-mediated diseases |
| WO2022182789A1 (en) * | 2021-02-24 | 2022-09-01 | Alladapt Immunotherapeutics, Inc. | Methods of treating allergies |
| WO2023200316A1 (ko) * | 2022-04-15 | 2023-10-19 | 사회복지법인 삼성생명공익재단 | 경구면역요법을 이용한 식품알레르기 치료서비스 제공방법, 이를 구현하기 위한 기록매체에 저장된 컴퓨터 프로그램 및 시스템 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3809767A (en) | 1969-05-12 | 1974-05-07 | Griffith Laboratories | Methods of making vegetable protein concentrates |
| DK1272213T3 (da) | 2000-04-06 | 2006-07-10 | Seer Pharmaceuticals Llc | Mikrobielt afgivelsessystem |
| CA2559458A1 (en) | 2004-03-19 | 2005-10-06 | Xiu-Min Li | Herbal therapy for the treatment of food allergy |
| US20090111702A1 (en) * | 2004-04-06 | 2009-04-30 | Mount Sinai School Of Medicine Office Of Industrial Liason | Methods of determining allergen response using microarray immunoassay techniques |
| CN102159201A (zh) | 2008-12-19 | 2011-08-17 | 莫茨药物股份两合公司 | 用于治疗肥大细胞介导的疾病的1-氨基-烷基环己烷衍生物 |
| AR081776A1 (es) | 2010-06-30 | 2012-10-17 | Novartis Ag | Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion |
| GB201104537D0 (en) | 2011-03-17 | 2011-05-04 | Cambridge Entpr Ltd | Treatment for peanut allergy |
| WO2014159609A1 (en) * | 2013-03-14 | 2014-10-02 | Allergen Research Corporation | Peanut formulations and uses thereof |
| CN105101994B (zh) | 2013-03-14 | 2018-10-12 | 艾慕恩治疗公司 | 用于口服脱敏的花生制剂的制备 |
| EP3185900A4 (en) | 2014-08-25 | 2018-05-02 | Aimmune Therapeutics, Inc. | Egg protein formulations and methods of manufacture thereof |
| SG10201913846XA (en) | 2017-01-13 | 2020-03-30 | Aimmune Therapeutics Inc | Methods of manufacture of nut flours and formulations for oral immunotherapy |
-
2018
- 2018-11-01 WO PCT/US2018/058777 patent/WO2019089978A1/en unknown
- 2018-11-01 US US16/178,502 patent/US11369676B2/en active Active
- 2018-11-01 EP EP18871949.6A patent/EP3703743A4/en active Pending
- 2018-11-01 CN CN201880071608.XA patent/CN111344010A/zh active Pending
- 2018-11-01 AU AU2018358125A patent/AU2018358125A1/en active Pending
- 2018-11-01 CA CA3080601A patent/CA3080601A1/en active Pending
- 2018-11-01 MX MX2020004683A patent/MX2020004683A/es unknown
- 2018-11-01 KR KR1020207015239A patent/KR20200083526A/ko not_active Application Discontinuation
-
2022
- 2022-05-24 US US17/752,639 patent/US20220288196A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220288196A1 (en) | 2022-09-15 |
| US20190167785A1 (en) | 2019-06-06 |
| CN111344010A (zh) | 2020-06-26 |
| CA3080601A1 (en) | 2019-05-09 |
| KR20200083526A (ko) | 2020-07-08 |
| AU2018358125A1 (en) | 2020-05-14 |
| EP3703743A4 (en) | 2021-12-08 |
| WO2019089978A1 (en) | 2019-05-09 |
| JP2021501763A (ja) | 2021-01-21 |
| EP3703743A1 (en) | 2020-09-09 |
| US11369676B2 (en) | 2022-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020004683A (es) | Metodos de inmunoterapia oral. | |
| MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
| PH12015502042A1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
| MX2021014709A (es) | Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes. | |
| EA201790398A1 (ru) | Способы лечения заболевания печени | |
| EA201790811A1 (ru) | Содержащие бактерии композиции и способы для улучшения видов поведения при нарушениях неврологического развития | |
| BR112018003110A2 (pt) | nanopartículas terapêuticas compreendendo um agente terapêutico e métodos de fabricação e uso dos mesmos | |
| MX2021010528A (es) | Metodos y composiciones para el tratamiento de las ulceras. | |
| MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
| CR20160582A (es) | Composición para tratar diabetes, que contienen un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada | |
| WO2015110923A3 (en) | Btk inhibitor for the treatment of chronic lymphocytic and small lymphocytic leukemia | |
| MY169328A (en) | Compositions for the treatment of dry eye | |
| MX2016009306A (es) | Reequilibrado inmunologico epicutaneo. | |
| MX2017000094A (es) | PRODUCTOS INMUNOGENICOS BASADOS EN SECUENCIAS DE AMINOACIDOS DE MUTEINA AMILOIDE ß (Aß) Y USOS DE LOS MISMOS. | |
| MX2020002216A (es) | Metodos y composiciones para detectar y tratar endometriosis. | |
| EA201790444A1 (ru) | Hsp90-направленная визуализация и терапия воспаления и инфекции | |
| EA201891664A1 (ru) | Составы/композиции, содержащие ингибитор btk | |
| BR112017001971A2 (pt) | ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais? | |
| BR112015024703A2 (pt) | formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose | |
| BR112018000252A2 (pt) | métodos e composições farmacêuticas para intensificar atividades de eliminação de célula nk | |
| PH12015502687A1 (en) | Marker for acid sphingomyelinase disorders and uses thereof | |
| MX2017007245A (es) | Metodos de tratamiento de la fibrosis. | |
| CY1122708T1 (el) | Ενωσεις οξα-διαζασπειρο με δραση εναντι του πονου | |
| CL2012000801A1 (es) | Composición farmacéutica en solución acuosa que comprende olopatadina y un compuesto derivado de quinolina sustituida, inhibidor de pde4; y uso para el tratamiento de una condición alérgica o inflamatoria del ojo, la nariz o la piel. | |
| WO2016100745A3 (en) | Methods and compositions related to transplant-associated thrombotic microangiopathy |